DS

Dimple Singh

Active Director Director DIN 08215266
DIN 08215266 First appointment Sep 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2018
Shareholding value •••• Premium profile

About Dimple Singh

Data last updated:

Dimple Singh is a Director at Welltech Pharmaceuticals Private Limited (since 2018). The company operates in Pharma. Welltech Pharmaceuticals Private Limited reported revenue of ₹31.8 Lakh (FY 2025).

DIN 08215266
Primary Designation Director
Industry Pharma
First Appointment 04 Sep 2018
Oldest Company Age 8 yrs
Largest company Welltech Pharmaceuticals Private Limited · ₹31.8 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Sep 20182018₹31.8 Lakh (FY 2025)Active

Board colleagues of Dimple Singh

Directorship timeline

Open interactive timeline →
Welltech Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Dimple Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dimple Singh

Dimple Singh currently holds 1 directorship: Welltech Pharmaceuticals Private Limited (Director, since 04 Sep 2018, revenue ₹31.8 Lakh (FY 2025)).

Dimple Singh was first appointed on 04 Sep 2018 as Director at Welltech Pharmaceuticals Private Limited.

The current boards of Dimple Singh's companies include Amit Singh (Welltech Pharmaceuticals Private Limited), Sangeeta Singh (Welltech Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available